Antipsychotics

Overview

A Brief History

The first antipsychotic, chlorpromazine (Thorazine), was identified in the early 1950s when French clinicians noticed that a compound being investigated as an anesthetic adjunct profoundly reduced agitation and hallucinations in patients with schizophrenia. Its introduction transformed psychiatric hospitals and is widely credited with launching modern psychopharmacology. Other first-generation agents — including haloperidol (Haldol), fluphenazine (Prolixin), perphenazine, and thiothixene — followed and remained the mainstay of psychotic illness treatment for decades.

The introduction of clozapine in the 1970s, followed by its formal re-emergence in the United States in 1989, marked the beginning of the second generation. Clozapine demonstrated unique efficacy in patients who had failed prior treatment, but its risk of agranulocytosis required intensive blood monitoring. Subsequent atypicals — risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, paliperidone, lurasidone, asenapine, iloperidone, cariprazine, brexpiprazole, and lumateperone — built on clozapine's pharmacology while attempting to avoid its hematological risk.

Typical vs. Atypical

The distinction between typical and atypical antipsychotics is partly historical and partly pharmacological. Typicals are defined by potent D2 dopamine receptor antagonism and a high rate of extrapyramidal motor side effects. Atypicals are defined by combined D2 and 5-HT2A serotonin receptor antagonism (or, in the case of aripiprazole, brexpiprazole, and cariprazine, partial D2 agonism), with lower rates of acute motor side effects but generally higher rates of metabolic side effects such as weight gain and dyslipidemia.

The categorical typical-versus-atypical distinction has become less useful clinically because individual medications within each group differ substantially. Some atypicals (e.g., risperidone at higher doses) behave much like typicals, and some typicals at low doses cause few motor side effects. Modern clinicians often think instead in terms of receptor binding profiles and individual side-effect risks.

The Scope of Use

Antipsychotics are no longer limited to schizophrenia. Atypical agents are widely used in bipolar disorder (for both mania and depression), as adjunctive treatment in major depressive disorder, for severe behavioral disturbances in autism spectrum disorder, for Tourette syndrome, and off-label for severe OCD, PTSD, agitation in delirium, and intractable insomnia. This expanded use has been controversial — particularly in elderly and pediatric populations — and is examined later in this guide.

How Antipsychotics Work

The Dopamine Hypothesis

Antipsychotics were developed before their mechanism was understood. Once it became clear that they all blocked dopamine D2 receptors, the dopamine hypothesis of schizophrenia emerged: psychotic symptoms — especially hallucinations and delusions — were thought to reflect excess dopaminergic activity in mesolimbic pathways. Decades of research have refined this hypothesis. Current models propose hyperactivity of dopamine in mesolimbic circuits (linked to positive symptoms) alongside hypoactivity in mesocortical pathways (linked to negative and cognitive symptoms).

Typical Antipsychotics: D2 Antagonism

First-generation antipsychotics produce their effect primarily through high-affinity blockade of dopamine D2 receptors throughout the brain. This blockade reduces dopaminergic transmission in the mesolimbic pathway, which is thought to underlie the reduction in hallucinations and delusions. The same blockade in other dopamine pathways causes the characteristic side effects: motor symptoms (nigrostriatal pathway), prolactin elevation (tuberoinfundibular pathway), and emotional blunting or anhedonia (mesocortical pathway).

Atypical Antipsychotics: D2 Plus 5-HT2A

Atypicals add antagonism of serotonin 5-HT2A receptors to D2 blockade. Blocking 5-HT2A receptors increases dopamine release in nigrostriatal and prefrontal regions, partially offsetting the D2 blockade in those areas. This is thought to reduce the rate of extrapyramidal motor side effects and may modestly improve negative and cognitive symptoms. Additional receptor activity at histamine H1, muscarinic, and adrenergic receptors contributes to sedation, weight gain, and orthostatic hypotension.

Partial Agonists

Aripiprazole (Abilify), brexpiprazole (Rexulti), and cariprazine (Vraylar) act as partial agonists at the D2 receptor rather than pure antagonists. In hyperdopaminergic states they reduce dopamine signaling; in hypodopaminergic states they provide a baseline level of activity. This "dopamine stabilizer" profile produces relatively low rates of motor side effects and prolactin elevation, though akathisia (motor restlessness) is a common side effect.

Clozapine's Distinct Profile

Clozapine binds D2 receptors with comparatively low affinity but engages a wide spectrum of other receptors, including 5-HT2A, 5-HT2C, muscarinic, histamine, and alpha-adrenergic receptors. Its anticholinergic activity reduces motor side effects, and its complex pharmacology may contribute to its uniquely strong efficacy in treatment-resistant schizophrenia and in reducing suicidality. The mechanisms behind clozapine's superior efficacy remain incompletely understood and are an active area of research.

Time Course

Although antipsychotics block dopamine receptors within hours, their full antipsychotic effect takes days to weeks to develop. Early benefits may include sedation and reduction of agitation. Improvements in hallucinations and delusions typically emerge over 2–6 weeks, with continued gains over months. Negative symptoms (apathy, social withdrawal) and cognitive symptoms respond less reliably and more slowly than positive symptoms.

Major Medications in This Class

First-Generation (Typical) Antipsychotics

• Chlorpromazine (Thorazine): The original antipsychotic. Lower-potency, with prominent sedation and anticholinergic effects.
• Haloperidol (Haldol): High-potency, widely used for acute psychosis and agitation; available as a long-acting decanoate injection.
• Fluphenazine (Prolixin): High-potency, available as a long-acting decanoate.
• Perphenazine (Trilafon): Mid-potency; included in the landmark CATIE schizophrenia trial.
• Thiothixene (Navane): High-potency.
• Loxapine (Loxitane, Adasuve): Mid-potency; an inhaled form is FDA-approved for acute agitation.
• Pimozide (Orap): Used primarily for Tourette syndrome.

Second-Generation (Atypical) Antipsychotics

• Clozapine (Clozaril, Versacloz): Uniquely effective in treatment-resistant schizophrenia and in reducing suicide risk in schizophrenia. Requires regular blood monitoring due to agranulocytosis risk.
• Risperidone (Risperdal): Broad-spectrum; high rates of prolactin elevation; available as a long-acting injection (Risperdal Consta).
• Paliperidone (Invega): Active metabolite of risperidone; available in monthly, three-monthly, and six-monthly injections.
• Olanzapine (Zyprexa): Highly effective but among the most metabolically risky atypicals.
• Quetiapine (Seroquel): Often used for bipolar depression and adjunctively for unipolar depression; sedating at lower doses.
• Aripiprazole (Abilify): Partial D2 agonist; generally weight-neutral but commonly causes akathisia.
• Ziprasidone (Geodon): Relatively weight-neutral; carries QT prolongation risk.
• Lurasidone (Latuda): Used for schizophrenia and bipolar depression; relatively favorable metabolic profile.
• Asenapine (Saphris, Secuado): Sublingual or transdermal formulations.
• Iloperidone (Fanapt): Requires slow titration to limit orthostatic hypotension.
• Cariprazine (Vraylar): Partial D2/D3 agonist; used in schizophrenia and bipolar disorder.
• Brexpiprazole (Rexulti): Partial D2 agonist; FDA-approved as adjunct for depression and for agitation in Alzheimer's disease.
• Lumateperone (Caplyta): Newer agent with a distinct receptor profile; approved for schizophrenia and bipolar depression.

Long-Acting Injectables (LAIs)

Long-acting injectable formulations release medication over weeks to months, supporting consistent treatment in patients for whom daily oral medication is challenging. LAIs available include haloperidol decanoate, fluphenazine decanoate, risperidone microspheres, paliperidone palmitate, olanzapine pamoate, aripiprazole monohydrate and lauroxil. LAIs are associated with reduced relapse and hospitalization in observational studies, particularly in schizophrenia and after first-episode psychosis.

FDA-Approved and Off-Label Uses

Schizophrenia and Schizoaffective Disorder

All antipsychotics are FDA-approved for the treatment of schizophrenia, the indication for which the class was originally developed. They reduce positive symptoms (hallucinations, delusions, disorganized thinking), reduce relapse risk during maintenance, and modestly improve overall functioning. Several atypicals are also approved for schizoaffective disorder. Clozapine has unique evidence for treatment-resistant schizophrenia — typically defined as failure of two adequate trials of other antipsychotics.

Bipolar Disorder

Many atypicals are FDA-approved for acute bipolar mania and for maintenance treatment, and several (quetiapine, lurasidone, olanzapine-fluoxetine combination, cariprazine, lumateperone) are approved for bipolar depression. The trend in modern bipolar care has been increased reliance on atypical antipsychotics, often alongside or in place of traditional mood stabilizers such as lithium and valproate.

Major Depressive Disorder

Aripiprazole, brexpiprazole, quetiapine extended-release, and the olanzapine-fluoxetine combination are FDA-approved as adjunctive treatment in major depression that has not adequately responded to antidepressants alone. They are not first-line monotherapy for depression.

Other Approved Uses

• Severe agitation associated with psychiatric illness (various oral and injectable formulations)
• Irritability in autism spectrum disorder (risperidone, aripiprazole, in pediatric populations)
• Tourette syndrome and tic disorders (haloperidol, pimozide, aripiprazole)
• Nausea and vomiting (some lower-potency typicals)
• Agitation in Alzheimer's disease (brexpiprazole — though black box warnings apply)

Off-Label Uses

Antipsychotics are widely prescribed off-label for severe OCD that has not responded to SSRIs, for treatment-resistant depression beyond approved indications, for borderline personality disorder, for PTSD, for severe anxiety, for delirium in hospitalized patients, and for chronic insomnia. Some off-label uses have evidence support; others do not, and off-label use in elderly and pediatric patients in particular has generated significant concern.

Common and Serious Side Effects

Extrapyramidal Symptoms (EPS)

EPS are motor side effects driven by D2 blockade in the nigrostriatal pathway. They include:

• Acute dystonia: Sudden involuntary muscle contractions, often of the neck, jaw, or eyes; usually within days of starting medication.
• Akathisia: A subjective and motor restlessness — an inability to sit still, often experienced as deeply distressing and sometimes mistaken for worsening anxiety.
• Drug-induced parkinsonism: Tremor, rigidity, bradykinesia, and shuffling gait resembling Parkinson's disease.
• Tardive dyskinesia (TD): Involuntary, often irreversible movements — most commonly of the face, mouth, tongue, and sometimes trunk and limbs — emerging after months to years of treatment. Rates are higher with typicals but TD occurs with atypicals as well.

VMAT2 inhibitors (valbenazine, deutetrabenazine) are FDA-approved treatments for tardive dyskinesia.

Metabolic Side Effects

Atypical antipsychotics — particularly clozapine and olanzapine, and to a lesser extent quetiapine and risperidone — can cause significant weight gain, dyslipidemia, insulin resistance, and type 2 diabetes. Metabolic complications contribute to the substantial reduction in life expectancy seen in chronic schizophrenia. Aripiprazole, brexpiprazole, ziprasidone, lurasidone, and lumateperone tend to be more metabolically neutral.

Prolactin Elevation

D2 blockade in the tuberoinfundibular pathway raises prolactin. Consequences can include galactorrhea (milk production unrelated to nursing), menstrual irregularities, sexual dysfunction, infertility, and, with chronic elevation, reduced bone mineral density. Risperidone, paliperidone, and high-potency typicals raise prolactin most strongly; aripiprazole tends to lower it.

Cardiac Effects

Many antipsychotics can prolong the QT interval, which raises the risk of dangerous arrhythmias. Ziprasidone, thioridazine, and intravenous haloperidol carry particularly notable QT effects. Some atypicals can cause orthostatic hypotension and tachycardia. Sudden cardiac death has been reported with antipsychotic use, particularly at higher doses and in vulnerable patients.

Sedation and Anticholinergic Effects

Lower-potency typicals (chlorpromazine), clozapine, olanzapine, and quetiapine commonly produce sedation, dry mouth, constipation, blurred vision, and urinary retention. In elderly patients, these effects can contribute to delirium and falls.

Neuroleptic Malignant Syndrome (NMS)

NMS is a rare but life-threatening reaction characterized by high fever, severe muscle rigidity, autonomic instability, altered consciousness, and elevated creatine kinase. It requires immediate medical attention and discontinuation of the offending agent. NMS can occur with any antipsychotic.

Clozapine-Specific Risks

• Agranulocytosis: A potentially life-threatening drop in white blood cell count. Patients enrolled in clozapine treatment undergo regular absolute neutrophil count (ANC) monitoring through a national registry.
• Myocarditis and cardiomyopathy: Highest risk in the first months of treatment.
• Seizures: Dose-related risk; higher than with most other antipsychotics.
• Hypersalivation, severe constipation, and bowel ischemia.

Other Effects

Photosensitivity, skin pigmentation changes (with chlorpromazine), seizure threshold lowering, hepatic enzyme elevations, and rare hematologic effects can occur. Patients on long-term treatment may also experience subtle cognitive and emotional flattening.

Drug Interactions and Warnings

FDA Black Box Warnings

• Increased mortality in elderly patients with dementia-related psychosis: All antipsychotics carry this warning. The risk includes cardiovascular events and pneumonia. Antipsychotic use for behavioral symptoms in dementia is now generally reserved for severe situations where non-pharmacological approaches have failed.
• Suicidality in young adults and adolescents: Applied to some atypicals when used as antidepressant adjuncts.
• Clozapine: Severe neutropenia, orthostatic hypotension, seizures, myocarditis, and the dementia mortality warning.

Common Drug Interactions

• CYP450 metabolism: Many antipsychotics are metabolized by CYP2D6 and CYP3A4; inhibitors or inducers (such as fluoxetine, paroxetine, carbamazepine, rifampin) can alter levels significantly.
• QT-prolonging drugs: Combining antipsychotics with other QT-prolonging agents (certain antiarrhythmics, methadone, some antibiotics) increases arrhythmia risk.
• CNS depressants: Combination with alcohol, benzodiazepines, opioids, or other sedatives increases sedation and respiratory depression risk.
• Levodopa and dopamine agonists: Antipsychotics can antagonize the effect of medications used in Parkinson's disease.
• Smoking: Cigarette smoking induces CYP1A2 and reduces blood levels of clozapine and olanzapine; abrupt cessation can lead to toxic levels.

Pregnancy and Lactation Warnings

Antipsychotic use in pregnancy involves balancing risks of untreated illness against medication exposure. Most agents cross the placenta. Third-trimester exposure has been associated with neonatal extrapyramidal and withdrawal symptoms. Decisions are individualized and made with specialist input.

Starting, Monitoring, and Stopping

Baseline Assessment

Before starting an antipsychotic, clinicians typically evaluate weight, blood pressure, fasting glucose, lipid panel, electrocardiogram (in patients with cardiac risk factors), liver function, complete blood count, and prolactin level when relevant. A personal and family history of cardiac disease, diabetes, and movement disorders is reviewed. For clozapine, baseline ANC and registry enrollment are required.

Ongoing Monitoring

Guidelines recommend periodic monitoring of:

• Weight, waist circumference, and BMI
• Fasting glucose or HbA1c
• Lipid panel
• Blood pressure
• Symptoms of EPS and tardive dyskinesia (standardized rating scales such as AIMS)
• Mental status, sleep, and adherence

Clozapine requires weekly ANC monitoring for the first six months, then every two weeks for the next six months, then monthly thereafter — protocol details may vary by region and updated guidelines.

Dose and Duration

Effective doses vary widely between agents and between patients. Modern practice generally favors the lowest effective dose, recognizing that higher doses do not necessarily improve efficacy but reliably increase side effects. For first-episode psychosis, doses are typically lower than for chronic illness.

Stopping or Switching

Abrupt discontinuation can cause withdrawal phenomena (cholinergic rebound, dyskinetic movements, insomnia) and increases relapse risk. Tapering is typically done over weeks to months under clinician supervision. Switching between agents is also done with careful overlap and monitoring. Decisions about long-term continuation versus tapering, especially after first-episode psychosis, are individualized and clinically nuanced.

Special Populations

Pregnancy and Postpartum

Untreated psychotic and bipolar illness in pregnancy carries serious risks to mother and fetus. Several antipsychotics have substantial reproductive safety data; others have less. Most antipsychotics are present in breast milk in measurable amounts. Treatment plans are individualized and ideally made with a reproductive psychiatry consultation.

Elderly Patients

Older adults are more susceptible to orthostatic hypotension, sedation, anticholinergic side effects, parkinsonism, falls, and the increased mortality associated with antipsychotic use in dementia. Doses are typically lower, with closer monitoring. Behavioral and psychological symptoms of dementia are first addressed with non-pharmacological strategies whenever possible.

Children and Adolescents

Antipsychotic use in young people has grown substantially. FDA approvals in pediatric populations include certain atypicals for schizophrenia (in adolescents), bipolar mania, irritability associated with autism, and tic disorders. Concerns include metabolic risk, prolactin effects on growth and bone development, and the appropriateness of use for non-approved conditions such as behavioral disturbances in foster care populations.

Comorbid Medical Conditions

Patients with diabetes, cardiovascular disease, seizure disorders, hepatic impairment, renal impairment, and Parkinson's disease require careful agent selection. For example, ziprasidone or aripiprazole may be preferred when metabolic risk is high, whereas quetiapine is sometimes used for psychosis in Parkinson's disease because of its lower D2 affinity. Drug-drug interactions with cardiac, anticonvulsant, or oncologic regimens are often complex.

Controversies and Modern Practice

Long-Term Use After First-Episode Psychosis

A long-running debate concerns the optimal duration of antipsychotic treatment after a first episode of psychosis. Traditional guidelines recommend continued treatment for at least one to two years, with longer maintenance for those with recurrent episodes. Some observational and trial data have raised questions about whether subgroups of patients might recover sufficiently to discontinue medication under careful supervision, while other data emphasize the high risk of relapse with discontinuation. Practice is evolving, and decisions are made individually.

The Clozapine Paradox

Despite its established superior efficacy in treatment-resistant schizophrenia and its evidence for reducing suicide, clozapine remains underused worldwide. Reasons include the burden of blood monitoring, prescriber unfamiliarity, side-effect concerns, and patient hesitancy. Many advocates argue that earlier clozapine use in treatment-resistant cases would substantially improve outcomes.

Metabolic Risk versus Symptom Control

Choosing between agents with strong efficacy but heavy metabolic burden (olanzapine, clozapine) and those with milder metabolic profiles but sometimes less symptom control involves trade-offs. Modern practice emphasizes integrated metabolic monitoring, lifestyle intervention, use of adjuncts (e.g., metformin to mitigate antipsychotic-induced weight gain in selected patients), and shared decision-making.

Antipsychotic Use in Non-Psychotic Conditions

The widespread off-label use of antipsychotics — for sleep, anxiety, behavioral disturbances in dementia, and personality disorders — is a frequent subject of debate. Critics argue that risks (metabolic, motor, cardiac) often outweigh benefits in non-psychotic indications, particularly when better-evidenced alternatives exist. Defenders point to clinical situations in which other options have failed and antipsychotics provide meaningful relief.

Long-Acting Injectables

LAIs were historically reserved for chronic, non-adherent patients but are increasingly considered earlier in illness, including after first-episode psychosis. Evidence suggests they reduce relapse and hospitalization, particularly in real-world populations. Critics note concerns about coercion and the experience of less control over treatment.

Brain Volume and Long-Term Effects

Some imaging studies have suggested that long-term antipsychotic use may be associated with subtle changes in brain volume. Interpretation is complicated by the effects of the underlying illness itself, substance use, and other factors. Most current evidence supports continued use when clinically indicated while remaining attentive to dose minimization.

What Patients Should Know

Setting Expectations

Antipsychotics typically begin to reduce acute symptoms within days but reach fuller effect over weeks. Side effects often appear before full benefits and may diminish over time or with dose adjustment. Open communication with the prescriber about what is and is not improving is essential.

Adherence

Many people who stop antipsychotics do so because of side effects, because they feel better and assume they no longer need medication, or because of concerns about long-term use. Discontinuation is a leading cause of relapse. Discussing concerns with a prescriber — rather than stopping silently — opens the door to dose adjustment, switching agents, or considering an LAI formulation.

Monitoring Your Own Health

Patients can support safer treatment by tracking weight, attending recommended labs, reporting new movements or restlessness, noting changes in libido or menstruation, and bringing up sedation, cognitive fog, or emotional changes. Quality-of-life issues are clinically relevant — not minor complaints.

Lifestyle and Adjunct Strategies

Diet, exercise, smoking cessation, sleep regularity, and substance use have substantial influence on outcomes. Cognitive remediation, social skills training, supported employment, and family psychoeducation complement medication in serious mental illness. Antipsychotics are most effective as part of integrated, recovery-oriented care — not as standalone treatment.

Stigma and Self-Understanding

Taking an antipsychotic does not define a person, and the conditions these medications treat are not character flaws. Many people on antipsychotics live full, productive lives — work, raise families, contribute creatively, and find meaning. Conversely, side effects, sedation, and emotional blunting are real concerns that deserve attention and dialogue.